2007
DOI: 10.1128/iai.01582-06
|View full text |Cite
|
Sign up to set email alerts
|

Immunogenic and Protective Potential of Mutans Streptococcal Glucosyltransferase Peptide Constructs Selected by Major Histocompatibility Complex Class II Allele Binding

Abstract: Mutans streptococcal glucosyltransferases (GTF) have been demonstrated to be effective components of dental caries vaccines. We had previously selected peptide subunits of GTF for vaccine development based on putative functional significance and conservation of GTF primary structure among enzyme isoforms. In this study, 20 20-mer linear GTF peptides were synthesized, 17 identified on the basis of the highest potential major histocompatibility complex (MHC) class II-binding activity using computer-generated alg… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
11
0

Year Published

2007
2007
2020
2020

Publication Types

Select...
7
2

Relationship

1
8

Authors

Journals

citations
Cited by 18 publications
(12 citation statements)
references
References 32 publications
(37 reference statements)
1
11
0
Order By: Relevance
“…1) that had been associated either with putative regions containing functional activity or with peptides that had MHC class II binding activity. Several of these peptides (GGY, CAT, Pep 11, and GLU) previously had been shown to induce a protective immune response to infection with cariogenic mutans strep- tococci (7,31,41). Figure 4 shows the median postinfection increases in the FI/IgA antibody value for each of the peptides assayed with all 22 salivas from both experiments.…”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“…1) that had been associated either with putative regions containing functional activity or with peptides that had MHC class II binding activity. Several of these peptides (GGY, CAT, Pep 11, and GLU) previously had been shown to induce a protective immune response to infection with cariogenic mutans strep- tococci (7,31,41). Figure 4 shows the median postinfection increases in the FI/IgA antibody value for each of the peptides assayed with all 22 salivas from both experiments.…”
Section: Resultsmentioning
confidence: 99%
“…Two monoepitopic peptide construct sequences (GLB and GLU) were based on Gtf sequences associated with putative glucan binding domains in the C-terminal third of the Gtf protein (1,17,43). Of further interest, several of these peptides (SYI, GGY, CAT, GLU, and Pep 11) have been shown to induce protective immune responses to the cariogenic effects of S. mutans and/or S. sobrinus infection (7,31,38,41). The Gtf/GbpB locations and sequences of the peptides are shown in Fig.…”
Section: Animals For the Immunization Experimentmentioning
confidence: 99%
“…Delivery of antigens with appropriate adjuvants via mucosal routes increases anti-GTF salivary (secretory) IgA and serum IgG levels and protects against experimental caries. Anti-caries protection in animals was obtained after immunization with intact GTF or glucan binding protein (GBP), their derived synthetic peptides, recombinant peptide-enzyme fusion proteins or, even DNA vaccines encoding one or more target antigens or their fragments [149,150]. Clearly, proof of principle exists for a dental caries vaccine.…”
Section: Caries Microbiome and Immunitymentioning
confidence: 99%
“…The adhesins interact with salivary proteins of the acquired pellicle on the tooth surface to promote adherence, glucosyltransferases catalyze glucan synthesis; Gbp increases the binding of MS to glucans deposited on tooth surfaces, contributing to the sucrose-dependent adherence to teeth [Lamont et al, 1991;Jenkinson et al, 1997]. Studies have shown that specific antibody induction to the above antigens [Taubman and Smith, 1977;Katz et al, 1993;Smith and Taubman, 1996], as well as to intrinsic peptides related to these antigens (such as QGQ, VAR, SYI, SIG, GGY, Pep 7, Pep 16, LVK, GLU), might prevent dental caries development in animal models [Smith et al, 1994a, b;Taubman et al, 1995;Smith et al, 1997Smith et al, , 1999Taubman et al, 2001;Smith et al, 2003Smith et al, , 2005Culshaw et al, 2007b]. Furthermore, some clinical trials [Smith and Taubman, 1990;Childers et al, 1999] suggest that adhesins I/II and Gtfs could be important in the development of vaccines [Smith, 2002;Smith and Mattos-Graner, 2008].…”
mentioning
confidence: 99%